Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by stockfyon Feb 25, 2021 4:54am
101 Views
Post# 32655547

RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

RE:RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The BuybackIt seems that we have a couple of haters here who post lies. It seems they bought CPH at $15 a few years ago.

Northface13 alias, get the facts straight. How you made so many inaccurate statements in such a brief comment is beyond me.

How did you miss that those who bought CPH at $1 in 2011, made 1,400% in 2015 when it exceeded $15?

Another lie you posted is that profitable debt-free CPH wrote off $5 million due to a dumb acquisition.

The fact is that CPH wrote off $5 million because CPH lost the lawsuit regarding Trulance, so it was not because of a dumb acqusition, facts below:

"The issue of whether Bausch Health is entitled to any additional amounts under the Agreement is deferred to a subsequent phase of the arbitration. As a result, the Company will impair approximately $5,400,000 USD in intangible assets related to upfront and milestone payments paid. "


Additionally, how did you miss that TRULANCE contributed ZERO revenue to CPH, so it has ZERO impact on CPH's top and bottom lines, facts below:

"Although, we are disappointed with the results of this arbitration it is important to note that Trulance was not currently being marketed or generating revenue for Cipher," said Craig Mull , Interim CEO. "Despite this news, we remain committed to driving profitability, strengthening the balance sheet, and looking for the right opportunities for growth."


Northforce13 wrote:

What ur missing is that 10 years ago the share price was the same as it is today.  So if you bought regular stocks 10 years ago ur up 150%.  If you bought this, ur up 0%. 

Cuz they sometimes make really dumb acquisitions then have to write them off, wiping out all their profits.

U shud maybe research these things before you buy, instead of buying then asking others what ur missing.

Like another poster pointed out, the latest write off is 5 mil, wiping out the entire year's profits thus far.  Maybe you missed that post. Or maybe you missed the press release from the company.



<< Previous
Bullboard Posts
Next >>